Anadrol 50 50mg/tab 100 Tabletten by Para Pharma

Usage

1. Confirm caloric surplus targets and daily protein intake (1.6–2.2 g/kg bodyweight) are in place before initiating the Oxymetholone bulking phase.
2. Begin at 25 mg per day for the first two weeks if this is your first Oxymetholone bulking cycle; advance to 50 mg per day only after confirming tolerance.
3. Take the daily 50 mg dose at a consistent time each day — preferably with a moderate-fat, moderate-protein meal to support gastric tolerance during high-calorie bulking intake.
4. Draw a hepatic function panel (ALT, AST, bilirubin) at the midpoint of the oral phase; adjust or cease the oral if enzyme values indicate excessive hepatic stress.
5. Ensure the injectable component of your bulking stack is already active and building toward steady-state concentration before the Oxymetholone phase ends, to prevent an androgenic gap at oral cessation.
6. After completing the oral bulking block, allow at least eight weeks before repeating an Oxymetholone phase; conduct a four-week post-cessation liver panel to confirm enzyme normalisation.

Warnings

Frequently asked questions

Is Para Pharma Anadrol 50 suitable as the primary oral compound in a bulking cycle?

Yes — Oxymetholone is one of the most established oral mass-building androgens specifically because it accelerates both nitrogen retention and red-cell expansion simultaneously during a caloric surplus. Its 50 mg per tablet concentration delivers the full oral bulking reference dose as a single analytically verified unit, making daily intake straightforward without tablet splitting.

How should daily Oxymetholone dose be structured during a dedicated mass-building phase?

Most bulking protocols begin at 50 mg per day for the first four weeks, with some practitioners using a two-week ramp starting at 25 mg before escalating. Total daily intake should remain tied to body weight and tolerance, and ALT/AST values drawn at the cycle midpoint determine whether the dose is maintained or reduced. Exceeding six weeks of continuous use without a liver-panel checkpoint is not supported by current harm-reduction guidance.

What injectable compounds are most logically paired with Anadrol 50 in a bulking stack?

Long-ester testosterone compounds — Testosterone Enanthate or Testosterone Cypionate — are the most common injectable partners in Oxymetholone bulking stacks because they provide sustained androgenic signalling as the oral's four-week window closes. The oral handles rapid early volumisation while the injectable sustains the anabolic environment for the remainder of the cycle, creating a sequential rather than redundant effect.

Why does the 50 mg per tablet concentration make Para Pharma Anadrol 50 particularly convenient for bulking cycle planning?

Standard bulking protocols for Oxymetholone anchor at 50 mg per day, meaning one tablet equals one complete daily dose. This removes any need for tablet splitting or combining multiple lower-dose units, which can introduce inconsistency. Because Para Pharma verifies per-tablet API content via reversed-phase HPLC content-uniformity testing — not batch-blend averages — each 50 mg dose is a confirmed value, not an estimate.

How does the 100-tablet pack count align with bulking cycle planning for Oxymetholone?

A 100-tablet pack at 50 mg per tablet covers a full four-week bulking block at 50 mg daily with surplus remaining for a titration week at 25 mg, or supports a five-week dose-escalation protocol from 25 mg to 50 mg without requiring a mid-cycle reorder. This pack size gives bulking cycle architects flexibility to adjust dose at phase boundaries without supply interruption. (2) angle_used

Manufacturer

Para Pharma's excipient selection framework for its oral tablet range addresses a constraint that becomes critical at the 50 mg active-ingredient level: that binder, filler, and disintegrant quantities must be precisely engineered to support tablet mechanical integrity without displacing API uniformity across the compression run. For Anadrol 50, the excipient matrix — covering microcrystalline cellulose as the primary filler, a starch-based disintegrant for dissolution rate control, and magnesium stearate as the lubricant phase — is specified to tolerances that prevent API migration within the granulate during high-speed compression. Critically, Para Pharma's release protocol requires that excipient-to-API ratio validation be conducted on finished tablets rather than on pre-compression blend samples alone, so that the confirmed 50 mg Oxymetholone value per unit accounts for any density or distribution variance introduced during the tabletting step itself. LAL endotoxin screening is applied to the raw Oxymetholone API before it enters the granulation stage, separating microbial purity verification from the finished-product analytical sequence.